Abstract
Purpose
To evaluate the impact of traditional French summer vacation on visual acuity and spectral domain-optical coherence tomography (SD-OCT) of Wet AMD patients being treated with intravitreal Ranibizumab.
Methods
This was a consecutive, comparative, single-centre, prospective analysis. All patients who were being treated with intravitreal injection of 0.5 mg ranibizumab at Cergy Pontoise Hospital, Department of Ophthalmology between July 2013 and September 2014 were included. Patients were divided into two groups: (A) patients who skipped one ranibizumab intravitreal injection during holidays, and (B) patients who received injection during their holidays. Evaluations occurred prior to traditional holiday (baseline) and 2 months later, consisting of BCVA using ETDRS, and a complete ophthalmic examination that included slit-lamp biomicroscopy, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), and spectral domain-optical coherence tomography (SD-OCT). All patients were being treated with PRN anti-VEGF regimen and criteria for reinjection included a visual acuity loss >5 ETDRS letters and/or an increase of central retinal thickness, presence of subretinal fluid, intraretinal fluid, or pigment epithelium detachment. If reinjection criteria were not met, patients were advised to return in 4 weeks.
Results
The mean visual acuity change was −0.071±0.149 (LogMAR) in group A and +0.003±0.178 in group B (P=0.041). At the second visit (2 months after preholidays visit), 61.8% of patients in group A had SRF and/or intraretinal cysts, and only 27.6% of patients in group B. There was a significant difference in the persistence of fluid between the two groups (P=0.007, χ2-test).
Conclusion
This cases series demonstrated the detrimental impact of holidays on visual acuity in patients treated with ranibizumab for AMD, which, in spite of their treatment regimen, still leave in vacation. Therefore, it is important to convey the message of treatment adherence to patients, despite their need of holidays.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bressler NM . Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291 (15): 1900–1901.
Wong TY, Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115 (1): 116–126.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1419–1431.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432–1444.
Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143 (4): 566–583.
Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age- related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148 (1): 43–58.
CATT Research Group, Martin DF, Maguire MG, Ying G, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age- related macular degeneration. N Engl J Med 2011; 364 (20): 1897–1908.
Coyle ME, Francis K, Chapman Y . Self-management activities in diabetes care: a systematic review. Aust Health Rev 2013; 37 (4): 513–522.
Chan KE, Thadhani RI, Maddux FW . Adherence barriers to chronic dialysis in the United States. J Am Soc Nephrol 2014; 25 (11): 2642–2648.
Grigoryan L, Pavlik VN, Hyman DJ . Patterns of nonadherence to antihypertensive therapy in primary care. J Clin Hypertens (Greenwich) 2013; 15 (2): 107–111.
Real JP, Granero GE, De Santis MO, Juarez CP, Palma SD, Kelly SP, Luna JD . Rate of vision loss in neovascular age-related macular degeneration explored. Graefes Arch Clin Exp Ophthalmol 2014; e-pub ahead of print 11 December 2014.
Muether PS, Hermann MM, Koch K, Fauser S . Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011; 249 (5): 633–637.
Kaiser PK . Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evid 2008; 2 (4): 273–294.
Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and metaanalysis. Ophthalmology 2008; 115: 116–126.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Massamba, N., Dirani, A., Knoeri, J. et al. Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab. Eye 29, 1453–1457 (2015). https://doi.org/10.1038/eye.2015.128
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2015.128
This article is cited by
-
Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis
Systematic Reviews (2023)
-
Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration
Ophthalmology and Therapy (2023)
-
Adhärenz bei der Anti-VEGF-Therapie – Überlegungen und praktische Empfehlungen
Der Ophthalmologe (2021)
-
The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol
International Ophthalmology (2021)
-
A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study
BMC Ophthalmology (2020)
